• The big deal of the day was Wyeth (WYE) and Catalyst Biosciences. The pair announced a deal worth up to $500 million for Catalyst’s Factor VIIa products to treat hemophilia and other bleeding conditions. Catalyst expects to receive $40 million from WYE over the next two years with $21 million paid upfront. [FierceBiotech]

• BioSante Pharmaceuticals and Cell Genesys are merging… [Pharmalive]

• Shareholders are PO’ed at UK biotech CEOS: easy with the salaries! The economy sucks, people! [WSJ]

• Comparative effectiveness is here in full-force. [Bloomberg]

• Pozen submits NDA for VIMOVO(TM). [Reuters]

• Pfizer/Wyeth still up in the air – in the EU that is. [Reuters]

• UK committing $250 million to biotech start-ups. [Bioworld]

• Finally, Geron (GERN), Novavax (NVAX) and Vical (VICL) were skyrocketing in the markets today. Geron announced a lucrative deal with GE, NVAX signed a deal with Spain’s ROVI Pharmaceuticals, VICL said its swine flu (H1N1) vaccine was highly effective in pre-clinical studies. VICL said it is ready to begin human testing. [MarketWatch]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts